Comparative Pharmacology
Head-to-head clinical analysis: HYTRIN versus TERAZOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYTRIN versus TERAZOSIN HYDROCHLORIDE.
HYTRIN vs TERAZOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.
Adults: Initial: 1 mg orally once daily at bedtime. May increase gradually to 2–5 mg once daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12–13 hours (range 10–15 h); clinical context: steady state achieved in 2–3 days; dose adjustment not required in renal impairment but caution in hepatic impairment.
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: ~40% as metabolites, <1% unchanged; biliary/fecal: ~60% as metabolites; total clearance 6.4 L/h.
Approximately 40% of the dose is excreted in urine (20% as unchanged drug) and 60% in feces via biliary elimination.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker